Mocht u de informatie op kanker-actueel waarderen dan wilt u ons misschien helpen met een donatie? Dat kan op bankrekening:

RABO 37.29.31.138 t.n.v. Stichting Gezondheid Actueel in Terneuzen.
Onze IBANcode is NL79 RABO 0372 9311 38
BIC/SWIFTCODE RABONNL2U

4 maart 2019: Bron: Clinical Neurology and Neurosurgery Volume 178, March 2019, Pages 31-35

Dit artikel heeft niets met kanker te maken maar vind dit toch demoiete ward te vermelden omdat heel veel mensen last hebben van migraine. Ik vertaal het niet omdat ik dit schrijf vanuit een internetcafe in Santo Domingo op een hele ude computer.

Maar magnesium via infuus geeft bij de helft van de patienten met migraine een duidelijke verlichting van pijn met 30 procent of meer. ook hadden minder patienten aanvullende injecties nodig om de migraine te kunnen verdragen.

Dit waren de kernpunten uit de studie:

Highlights

Retrospective analysis of 234 patients who received intravenous magnesium for status migrainosus.
44% of patients did not require additional intramuscular medications for pain, over half of whom (59%) experienced pain reduction of 30% or more.

Patients with less severe pain tended to have a better response than patients with more severe pain.

Maar lees het studierapport: Experiences of an outpatient infusion center with intravenous magnesium therapy for status migrainosus

Hier het abstract van de studie:

Clinical Neurology and Neurosurgery Volume 178, March 2019, Pages 31-35

Experiences of an outpatient infusion center with intravenous magnesium therapy for status migrainosus

https://doi.org/10.1016/j.clineuro.2019.01.007

Abstract

Objectives

Exploratory study to investigate the effectiveness of intravenous magnesium as an abortive for status migrainosus in an outpatient infusion center, and characterize the patients who benefit from the therapy.

Patients & methods

Retrospective analysis of 234 migraine patients who received IV magnesium as a headache abortive, at the headache clinic of University of Southern California. Additional intramuscular (IM) injections for nausea (prochlorperazine, odansetron, metoclopramide) or for refractory pain (ketorolac, dexamethasone, sumatriptan, dihydroergotamine), were administered as necessary. Immediately before and after treatment, self-reported pain levels were recorded using an 11-point numeric pain rating scale (0–10).

Results

Our patient sample has a mean age of 44 years and was predominantly female (79%). 36 (19%) had migraine with aura. Overall, pain score decreased from 5.46±2.39 to 3.56 ± 2.75 (P < 0.001) after magnesium infusion. One hundred twenty-seven (54%) patients had clinically significant pain reduction, as defined by pain decrease ≥ 30%. One hundred and four patients (44%) received IV magnesium and did not require additional intramuscular (IM) medications for pain. In patients who did not receive additional IM medications for pain, pain score decreased from 4.76 ± 2.41 to 2.95 ± 2.70 (p < 0.001), and 61 out of 104 (59%) experienced ≥ 30% pain reduction. Patients with less severe pain tended to have a better response than patients with more severe pain, as patients with ≥30% pain reduction had a significantly lower pre-treatment pain score (p = 0.018).

Conclusion

For a subset of patients with status migrainosus, IV magnesium therapy results in clinically significant pain relief without the need for intramuscular pain medications. Therefore, IV magnesium may be useful as a cost-effective first-line parental therapy for status migrainosus, especially for patients who initially present with lower pain intensity.